Revance Therapeutics Inc (NASDAQ:RVNC)
| 32.20 Delayed Data As of Mar 31 |  +1.07 / +3.44%Today’s Change | 11.27 Today|||52-Week Range 36.61 | +74.43% Year-to-Date |
Largest transactions by value over
| Name | Type | Date | Shares traded | Share price | Transaction value | Since transaction |
|---|---|---|---|---|---|---|
Foley Mark J Chief Executive Officer |  Sale | 3/09/2023 | 70,390 | $31.59 | $2.2M | +4.00% |
Foley Mark J Chief Executive Officer | Sale | 10/13/2022 | 49,274 | $26.97 | $1.3M | +19.43% |
Sjuts Dustin S President | Sale | 3/09/2023 | 21,508 | $31.59 | $679.4K | +4.00% |
Schilke Tobin C Chief Financial Officer | Sale | 3/09/2023 | 18,517 | $31.59 | $585.0K | +4.00% |
Moxie Dwight Secretary, Senior Vice President & General Counsel | Sale | 3/09/2023 | 18,496 | $31.59 | $584.3K | +4.00% |
Moxie Dwight Secretary, Senior Vice President & General Counsel | Sale | 9/14/2022 | 11,000 | $27.07 | $297.8K | +17.00% |
Moxie Dwight Secretary, Senior Vice President & General Counsel | Sale | 3/15/2023 | 7,330 | $30.65 | $224.7K | +5.09% |
Foley Mark J Chief Executive Officer | Sale | 3/15/2023 | 5,341 | $30.65 | $163.7K | +5.09% |
Schilke Tobin C Chief Financial Officer | Sale | 3/15/2023 | 3,739 | $30.65 | $114.6K | +5.09% |
Schilke Tobin C Chief Financial Officer | Sale | 3/01/2023 | 3,201 | $33.50 | $107.2K | -0.12% |
Page of 4